Of patients with a BRCA mutation , median PFS was significantly longer in the olaparib group than in the placebo group ( 112 months [ 95 % CI 83-not calculable ] vs 43 months [ 30-54 ] ; HR 018 [ 010-031 ] ; p < 00001 ) ; similar findings were noted for patients with wild-type BRCA , although the difference between groups was lower ( 74 months [ 55-103 ] vs 55 months [ 37-56 ] ; HR 054 [ 034-085 ] ; p = 00075 ) .